Compare · CDT vs NVO
CDT vs NVO
Side-by-side comparison of CDT Equity Inc. (CDT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 13758.8x CDT ($13.4M).
- NVO has been more active in the news (5 items in the past 4 weeks vs 4 for CDT).
- NVO has more recent analyst coverage (25 ratings vs 0 for CDT).
- Company
- CDT Equity Inc.
- Novo Nordisk A/S
- Price
- $2.75-7.09%
- $41.18+6.93%
- Market cap
- $13.4M
- $183.82B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 4
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CDT
- SEC Form S-3 filed by CDT Equity Inc.
- CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
- SEC Form 10-K filed by CDT Equity Inc.
- CDT Notes Sarborg Publication of PRISM Framework Expanding AI
- SEC Form 424B5 filed by CDT Equity Inc.
- SEC Form NT 10-K filed by CDT Equity Inc.
- SEC Form 4 filed by Taylor Mark Andrew
- SEC Form 3 filed by new insider Taylor Mark Andrew
- CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
- CDT Equity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S